The invention relates to a medicament for preventing and/or treating fatty liver which comprises as an active ingredient cilostazol or a pharmaceutically acceptable salt thereof.

Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipo...

The present invention provides an orally disintegrating powder comprising cilostazol as an active ingredient and mannitol in an amount of 70% by weight or more which can be taken without water and can be disintegrated in the oral cavity. Said powder is suitable for patients to whom cilostazol is administered especially for aged patients and patients suffering from dysphagia.

PURPOSE: A pharmaceutical composition containing cilostazol and a ginkgo leaf extract for preventing or treating atherosclerosis is provided to prevent an atherosclerotic lesion and inflammation and to suppress the generation of reactive oxygen, thereby preventing or treating atherosclerosis. CONSTITUTION: A pharmaceutical composition for preventing or treating atherosclerosis contains cilostazol and a ginkgo leaf extract as active ingredients, which are mixed in a weight ratio of 1:0.1-1:4.8. T...

Provided is a pharmaceutical composition for the treatment and prevention of alcoholic liver diseases, including cilostazol as an active ingredient. Cilostazol inhibits expression levels of TNF-alpha and FAS (fatty acid synthase) gene in a concentration-dependent manner, and also significantly inhibits the activity of caspase-3. Accordingly, cilostazol shows superior effects for the treatment or prevention of alcoholic liver diseases, in particular, alcoholic hepatitis compared to pentoxifylline...

PURPOSE: A pharmaceutical composition containing cilostazol and a ginkgo leaf extract for preventing or treating hearing loss is provided to suppress apoptosis of auditory cells caused by generation of reactive oxygen species (ROS) thereby effectively preventing or treating noise deafness or ototoxic deafness. CONSTITUTION: A pharmaceutical composition for preventing or treating hearing loss contains cilostazol and a gingko leaf extract as active ingredients which are mixed in a weight ratio of ...

Provided is a pharmaceutical composition for the treatment and prevention of alcoholic liver diseases including cilostazol as an active ingredient. Cilostazol inhibits expression levels of TNF-alpha and FAS (fatty acid synthase) gene in a concentration-dependent manner and also significantly inhibits the activity of caspase-3. Accordingly cilostazol shows superior effects for the treatment or prevention of alcoholic liver diseases in particular alcoholic hepatitis compared to pentoxifylline whic...

The present invention relates to a pharmaceutical composition for preventing or treating hearing loss, containing cilostazol and a ginkgo leaf extract as active ingredients. The pharmaceutical composition can effectively prevent or treat noise-induced hearing loss or ototoxic hearing loss by inhibiting the apoptosis of hair cells due to the generation of reactive oxygen species (ROS).